SEC Form 4 · accession 0001144204-17-048544
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony S. Fiorino
Officer — Chief Medical Officer and COO
Period of report
Sep 14, 2017
Accepted (ET)
Sep 18, 2017 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $1.10 | Sep 14, 2017 | A | 90,000 | A | Sep 14, 2017 | Sep 14, 2027 | Common Stock | 90,000 | 90,000 | D |
Explanation of responses
- F115% of the options shall vest ninety (90) days following the date of grant; 15% on the first-year anniversary of the date of grant (the "Anniversary") and 70% in equal portions at the end of each three (3) month period over the course of a two (2) year period commencing on the Anniversary.